Bard gets mistrial in vaginal mesh suit; SynGen wins FDA nod for blood processor;

 @FierceMedDev: AngioDynamics' FY 2013 reflects a partial upswing. Story | Follow @FierceMedDev

 @MarkHFierce: Give us your FMD Fierce 15 nominations today - Device and Dx nominations welcome. Submit here | Follow @MarkHFierce

 @DamianFierce: AstraZeneca signs up with genomics outfit Blackfield for cancer R&D. More | Follow @DamianFierce

> C.R. Bard ($BCR) got a break late last week when a federal judge declared a mistrial in a product liability lawsuit concerning the company's vaginal mesh devices. A witness' testimony brought on the action. Story

> The FDA has signed off on a new test designed to more quickly determine the effectiveness of steam sterilization for reusable medical devices. Item

> SynGen gained FDA 510(k) clearance for its new system designed to process umbilical cord blood. Item

> Life Technologies ($LIFE) launched the EVOS FL Auto Imaging System, a lab-based cell monitoring device the company said is priced to penetrate emerging markets. More

> A retired cardiovascular surgeon says he's developed a new approach for an artificial pancreas. Story

> Sweden's Episurf Medical won a CE mark for its new personalized knee implant. Item

> Australian researchers are designing an eye implant that would release drugs after a laser targets it. Story

Biotech News

 @FierceBiotech: ICYMI last week: The biotech IPO scene turns red hot. Special report | Follow @FierceBiotech

 @JohnCFierce: Vivus pushes back shareholder meeting, a sure sign they are losing the fight with FMC. Report | Follow @JohnCFierce

 @RyanMFierce: Europe eyes social media and mobile for data on bad drug reactions. Story | Follow @RyanMFierce

 @EmilyMFierce: You can't patent human genes. So why are genetic testing companies getting sued? Article | Follow @EmilyMFierce

> Is this the NIH Francis Collins wanted to create? Editor's Corner

> Ipsen bags a development platform with $207M Syntaxin buyout. Story

> Buzz: Why is Roche considering a big buyout of Alexion? Report

Pharma News

 @FiercePharma: AstraZeneca CFO jumps ship in latest executive switcheroo. News | Follow @FiercePharma

 @EricPFierce: Novartis CEO Jimenez says China is a difficult market, but worth it. I wonder if GSK agrees right now. Article | Follow @EricPFierce

 @CarlyHFierce: Here's Vivus' release re: delaying its shareholder meeting - says First Manhattan made false statements. Release | Follow @CarlyHFierce

> Roche may want Alexion, but is the price right? Story

> China calls GSK 'godfather' in alleged bribery scheme. News

CRO News

> Corgenix signs CMO deal with EDP Biotech. Item

> Theorem, Emergo team up for devices and diagnostics. News

> NIH, industry back out of India as trials slow to standstill. Article

> Catalent inks Biota flu deal, shifts delivery biz. Story

Biotech IT News

> Europe eyes social media and mobile for data on bad drug reactions. News

> High-profile VC Sequoia backs clinical tech startup Comprehend in $8.4M round. Story

> Boehringer Ingelheim expands use of Big Data tech for pharma research. Article

> ChemAxon extends pharma software streak with Schrödinger deal. Item

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.